S10OD036394
Project Grant
Overview
Grant Description
Novaseq X Plus, advanced next generation sequencer - abstract replacing the Illumina Novaseq 6000 next generation sequencing (NGS) system with the new Illumina Novaseq X Plus NGS system will improve services provided by the UAMS Genomics Core Facility to all users by: i) reducing the cost of sequencing by up to ~80% compared to the current system (Novaseq 6000), ii) accommodating advanced chemistries allowing for NGS read lengths up to 7KB and thus improving the specificity of NGS findings, and iii) allowing for the storage of NGS reagents at room temperature versus refrigeration.
The Novaseq X Plus system will reside in the University of Arkansas for Medical Sciences (UAMS) Genomics Core Facility, which is an important resource for faculty and students in Arkansas who are engaged in research that impacts human health. The mission of the UAMS Genomics Core Facility is to provide investigators with convenient access, at affordable prices, to the latest technologies for advanced molecular profiling of biological samples. Importantly, this includes NGS-based studies, experiments, and assays.
Services are provided to investigators at UAMS, other universities in Arkansas including faculty and students from undergraduate institutions in the Arkansas INBRE network, and importantly NIH Institutional Development Award (IDEA) centers in Arkansas. Three funded IDEA center grants on the UAMS campus that will be a part of the major users group, which will occupy the bulk of time on this new instrument are: i) the Center for Translational Pediatric Research (P20GM121293), ii) the Center for Musculoskeletal Disease Research (P20GM125503) and, iii) the Center for Studies of Host Response to Cancer Therapy (P20GM109005).
Additional members of the major user group will predominately be involved with research activities related to obtaining NCI Cancer Center designation for UAMS. Services provided by the UAMS Genomics Core may be “all inclusive” and consist of consultation and in-person meeting(s) concerning an investigator’s question (hypothesis) along with assistance and guidance for an experimental design. Initial meetings are essential in order to manage new users’ expectations and foster their success.
Additional NGS service components include: i) sample preparation with QA/QC validation, ii) running the sample on the NGS instrument and, iii) bioinformatics pipeline processing (data analysis). The UAMS Genomics Core Facility is fully supported and supplemented by the UAMS Rockefeller Cancer Institute and the College of Medicine. State-of-the-art genomic scientific instrumentation is essential to facilitate novel research (eg, advanced liquid biopsy assays) for faculty and students in Arkansas.
The goal of obtaining NCI Cancer Center designation by UAMS will be strengthened by the addition of the Novaseq X Plus NGS system.
The Novaseq X Plus system will reside in the University of Arkansas for Medical Sciences (UAMS) Genomics Core Facility, which is an important resource for faculty and students in Arkansas who are engaged in research that impacts human health. The mission of the UAMS Genomics Core Facility is to provide investigators with convenient access, at affordable prices, to the latest technologies for advanced molecular profiling of biological samples. Importantly, this includes NGS-based studies, experiments, and assays.
Services are provided to investigators at UAMS, other universities in Arkansas including faculty and students from undergraduate institutions in the Arkansas INBRE network, and importantly NIH Institutional Development Award (IDEA) centers in Arkansas. Three funded IDEA center grants on the UAMS campus that will be a part of the major users group, which will occupy the bulk of time on this new instrument are: i) the Center for Translational Pediatric Research (P20GM121293), ii) the Center for Musculoskeletal Disease Research (P20GM125503) and, iii) the Center for Studies of Host Response to Cancer Therapy (P20GM109005).
Additional members of the major user group will predominately be involved with research activities related to obtaining NCI Cancer Center designation for UAMS. Services provided by the UAMS Genomics Core may be “all inclusive” and consist of consultation and in-person meeting(s) concerning an investigator’s question (hypothesis) along with assistance and guidance for an experimental design. Initial meetings are essential in order to manage new users’ expectations and foster their success.
Additional NGS service components include: i) sample preparation with QA/QC validation, ii) running the sample on the NGS instrument and, iii) bioinformatics pipeline processing (data analysis). The UAMS Genomics Core Facility is fully supported and supplemented by the UAMS Rockefeller Cancer Institute and the College of Medicine. State-of-the-art genomic scientific instrumentation is essential to facilitate novel research (eg, advanced liquid biopsy assays) for faculty and students in Arkansas.
The goal of obtaining NCI Cancer Center designation by UAMS will be strengthened by the addition of the Novaseq X Plus NGS system.
Funding Goals
THE OFFICE OF RESEARCH INFRASTRUCTURE PROGRAMS (ORIP) IS A PROGRAM OFFICE IN THE DIVISION OF PROGRAM COORDINATION, PLANNING, AND STRATEGIC INITIATIVES (DPCPSI) DEDICATED TO SUPPORTING RESEARCH INFRASTRUCTURE AND RELATED RESEARCH RESOURCE PROGRAMS. ORIP CONSISTS OF THE DIVISION OF COMPARATIVE MEDICINE (DCM) AND THE DIVISION OF CONSTRUCTION AND INSTRUMENTS (DCI).
Grant Program (CFDA)
Awarding Agency
Place of Performance
Arkansas
United States
Geographic Scope
State-Wide
University Of Arkansas For Medical Sciences was awarded
Project Grant S10OD036394
worth $750,000
from the National Institute of Allergy and Infectious Diseases in June 2024 with work to be completed primarily in Arkansas United States.
The grant
has a duration of 1 year and
was awarded through assistance program 93.351 Research Infrastructure Programs.
The Project Grant was awarded through grant opportunity Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed).
Status
(Complete)
Last Modified 12/5/25
Period of Performance
6/15/24
Start Date
6/14/25
End Date
Funding Split
$750.0K
Federal Obligation
$0.0
Non-Federal Obligation
$750.0K
Total Obligated
Activity Timeline
Transaction History
Modifications to S10OD036394
Additional Detail
Award ID FAIN
S10OD036394
SAI Number
S10OD036394-3274535856
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75AGNA NIH AGGREGATE FINANCIAL ASSISTANCE DATA AWARDING OFFICE
Funding Office
75NA00 NIH OFFICE OF THE DIRECTOR
Awardee UEI
VDFYLZPJEAV6
Awardee CAGE
1QJY4
Performance District
AR-90
Senators
John Boozman
Tom Cotton
Tom Cotton
Modified: 12/5/25